Day One Biopharmaceuticals, Inc. (DAWN)

Market Cap	2.19B +84.3%
Revenue (ttm)	158.18M +20.6%
Net Income	-107.32M
EPS	-1.04
Shares Out	103.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,372,872
Open	21.13
Previous Close	12.78
Day's Range	21.08 - 21.23
52-Week Range	5.64 - 21.23
Beta	-1.25
Analysts	Strong Buy
Price Target	27.61 (+30.24%)
Earnings Date	Feb 24, 2026

About DAWN

Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2021
• Employees: 178
• Stock Exchange: NASDAQ
• Ticker Symbol: DAWN
• Website: https://dayonebio.com

Financial Performance

In 2025, DAWN's revenue was $158.18 million, an increase of 20.60% compared to the previous year's $131.16 million. Losses were -$107.32 million, 12.4% more than in 2024.

Analyst Summary

According to 10 analysts, the average rating for DAWN stock is "Strong Buy." The 12-month stock price target is $27.61, which is an increase of 30.24% from the latest price.

Price Target

$27.61

(30.24% upside)

Analyst Consensus: Strong Buy